Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Zi-Yang Shi; Ying Fang; Peng-Peng Xu; Hong-Mei Yi; Jian-Feng Li; Yan Dong; Yue Zhu; Meng-Ke Liu; Di Fu; Shuo Wang; Qing Shi; Rong Shen; Hui-Juan Zhong; Chao-Fu Wang; Shu Cheng; Li Wang; Feng Liu; Wei-Li Zhao

doi:10.1002/ctm2.1691

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1691 DOI: 10.1002/ctm2.1691

LETTER TO THE JOURNAL

Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor

Author information +

History +

PDF

Cite this article

Download citation ▾

Zi-Yang Shi, Ying Fang, Peng-Peng Xu, Hong-Mei Yi, Jian-Feng Li, Yan Dong, Yue Zhu, Meng-Ke Liu, Di Fu, Shuo Wang, Qing Shi, Rong Shen, Hui-Juan Zhong, Chao-Fu Wang, Shu Cheng, Li Wang, Feng Liu, Wei-Li Zhao. Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor. Clinical and Translational Medicine, 2024, 14(6): e1691 DOI:10.1002/ctm2.1691

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.